Pembrolizumab

RAHWAY, N.J., April 2, 2026 Merck (MSD) has secured a major regulatory milestone as the European Commission approves KEYTRUDA®...

CRANFORD, N.J., March 31, 2026 Citius Oncology, Inc. has reported strong early momentum following the U.S. launch of its...

BOSTON, Mass., Feb. 20, 2026 — New clinical findings presented at a major oncology symposium demonstrate that ficerafusp alfa...

RAHWAY, N.J., Dec. 17, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 (EV-304)...

Rahway, N.J., Nov. 21, 2025 — In a major advancement for oncology treatment, the U.S. Food and Drug Administration...

CAMBRIDGE, MA – October 21, 2025 – Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company pioneering therapies that target...

NUTLEY, N.J., Oct. 2, 2025 — Eisai Inc. announced today the presentation of its expansive oncology portfolio at the...

RAHWAY, N.J. – September 20, 2025 — Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA)...